Dublin, Oct. 19, 2017 -- The "Global Surgical Robots Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024" report has been added to Research and Markets' offering.
Global surgical robots market is projected to reach USD 14,717.9 million by 2024 from USD 5,283.5 million in 2016, at a CAGR of 13.7% in the forecast period 2017 to 2024.
Intutive Surgical, Inc. is dominating the surgical robots market following by
- Accuray Inc.
- Mazor Robotics
- Restoration Robotics, Inc.
- MedTech S.A.
- Verb Surgical Inc.
- Auris Surgical Robots
- MAZOR Robots
- Hansen Medical
- ReWalk Robots
- Hocoma AG
Key Topics Covered:
1. Introduction
2. Market Segmentation
3. Market Overview
3.1. Drivers
3.1.1. Rising Ageing Population
3.1.2. Rising Case of Acute and Chronic Diseases
3.1.3. Better Benefits to Patients and Surgeons
3.2. Restraints
3.2.1. Regulatory Scenario
3.2.2. Shortage of Trained Surgeons
3.2.3. High Cost of the Equipment and Surgery
3.3. Opportunities
3.3.1. Mergers and Acquisitions to Expand Business
3.3.2. Increasing Need of Reducing Healthcare Costs in U.S
3.4. Challenges
3.4.1. Increasing Competitors
3.4.2. High Entry Level Costs
3.4.3. High Level Entry Barriers Due to Patents
4. Premium Insights
5. Report Description
6. Global Surgical Robots Market, by Product Type
6.1. Overview
6.2. Systems
6.3. Instruments
6.4. Accessories and Services
7. Global Surgical Robots Market, by Brands
7.1. Overview
7.2. Da Vinci Surgical System
7.3. Cyberknife
7.4. Renaissance
7.5. Artas
7.6. Rosa
8. Global Surgical Robots Market, by Application
8.1. Introduction
8.2. General Surgery
8.3. Urological Surgery
8.4. Gynecological Surgery
8.5. Gastrointestinal Surgery
8.6. Radical Prostatectomy
8.7. Cardiothoracic Surgery
8.8. Colorectal Surgery
8.9. Radiotherapy
8.10. Others
9. Global Surgical Robots Market, by Geography
10. Global Surgical Robots Market, Company Landscape
10.1. Company Share Analysis: Global
10.2. Company Share Analysis: North America
10.3. Company Share Analysis: Europe
10.4. Company Share Analysis: Asia-Pacific
10.5. Recent Development by Company: Global
10.6. Approvals by Company: Global
10.7. Recent Developments by Type: Global
11. Company Profiles
- Accuray Inc.
- Auris Surgical Robots
- Hansen Medical
- Hocoma AG
- Intutive Surgical, Inc.
- Mazor Robotics
- Medrobotics Corporation
- MedTech S.A.
- Restoration Robotics, Inc.
- ReWalk Robots
- Stryker Corporation
- Titan Medical Inc
- Verb Surgical Inc.
- Virtual Incision Corporation
For more information about this report visit https://www.researchandmarkets.com/research/jvs4mx/global_surgical
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Robotics


Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 



